|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 157.20 ILa | -1.38% |
|
-8.76% | -47.70% |
| 06-02 | Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab | CI |
| 05-20 | Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | -1.38% | -8.76% | -24.71% | -40.86% | -47.70% | -68.78% | -95.23% | -98.59% | -99.35% | 5.6M | |
| +0.34% | +1.09% | +1.54% | +7.22% | -6.95% | -10.67% | -5.05% | -22.87% | +210.42% | 43.13B | |
| +1.73% | +3.59% | +9.40% | +73.12% | +108.17% | +318.08% | +564.04% | +403.52% | - | 34.65B | |
| +0.61% | +1.34% | -12.39% | -1.26% | -10.54% | +10.00% | +46.20% | -18.26% | +749.91% | 30.03B | |
| +0.02% | -5.93% | -0.05% | +1.05% | -25.55% | +8.45% | -21.44% | -31.22% | +162.53% | 28B | |
| -1.06% | -3.71% | -10.96% | -12.41% | -2.25% | +9.08% | +19.56% | -25.20% | +149.52% | 24.45B | |
| -1.23% | +2.11% | -7.71% | - | - | - | - | - | - | 14.34B | |
| -0.99% | -2.53% | +5.28% | +0.70% | -18.87% | +47.29% | +102.88% | +149.25% | - | 13.14B | |
| +1.54% | +0.16% | +1.44% | +3.93% | +1.73% | +6.69% | +8.89% | -32.18% | +94.22% | 12.53B | |
| +2.39% | +2.61% | +0.44% | +6.90% | -4.07% | +102.86% | +84.20% | +101.35% | +235.95% | 12.25B | |
| -3.61% | -4.73% | +20.51% | +41.15% | -22.77% | -3.93% | -38.09% | -33.72% | +110.45% | 11.18B | |
| -5.88% | -8.54% | +3.62% | +1.90% | -18.97% | -29.95% | - | - | - | 9.13B | |
| -4.02% | -1.00% | +15.35% | +8.02% | -5.44% | +11.47% | -27.32% | -49.66% | +100.05% | 9.07B | |
| -1.86% | -3.67% | +13.26% | +18.20% | -8.98% | +23.13% | -11.07% | -50.12% | +117.91% | 8.91B | |
| +7.47% | +14.69% | -11.69% | +1.70% | +2.93% | +616.56% | +1,658.78% | +3.04% | - | 7.87B | |
| +0.88% | +0.82% | -18.98% | -21.57% | -28.74% | +1,534.29% | +440.30% | +193.33% | +1,440.39% | 7.77B | |
| -1.81% | -1.97% | +3.16% | -9.14% | -23.36% | -26.29% | -28.44% | -31.50% | +43.91% | 7.64B | |
| +2.29% | +3.74% | +25.05% | +63.48% | +64.47% | +58.20% | +36.84% | +89.85% | +6.92% | 7.5B | |
| +9.97% | +16.19% | +26.06% | +27.65% | +27.81% | +116.81% | +324.46% | +123.53% | - | 7.44B | |
| +1.92% | +2.29% | +15.97% | +16.34% | +31.70% | +115.65% | +317.68% | +165.05% | - | 7.26B | |
| Average | +0.63% | +0.03% | +2.73% | +9.80% | +0.66% | +149.42% | +187.62% | +46.42% | +255.60% | 14.82B | |
| Weighted average by Cap. | +0.48% | +0.01% | +1.80% | +14.06% | +7.34% | +113.50% | +159.69% | +60.69% | +289.68% |
- Stock Market
- Stocks
- EVGN Stock
- Sector Evogene Ltd.
Select your edition
All financial news and data tailored to specific country editions
